Radiomics can predict tumour response in patients treated with Nivolumab for a metastatic renal cell carcinoma: an artificial intelligence concept. Article uri icon

Overview

publication date

  • July 6, 2020

Research

keywords

  • Artificial Intelligence
  • Carcinoma, Renal Cell
  • Immune Checkpoint Inhibitors
  • Kidney Neoplasms
  • Nivolumab

Identity

Scopus Document Identifier

  • 85087505910

Digital Object Identifier (DOI)

  • 10.1007/s00345-020-03334-5

PubMed ID

  • 32632555

Additional Document Info

volume

  • 39

issue

  • 9